182 results on '"Goldsmith, Kelly C"'
Search Results
2. Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma
3. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
4. Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma
5. Trends in analgesia‐sedation of pediatric patients receiving I‐131 MIBG in the pediatric intensive care unit: A report from the Pediatric Health Information System database.
6. Reduced ER–mitochondria connectivity promotes neuroblastoma multidrug resistance
7. Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care
8. The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1
9. Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement
10. A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors
11. Identification of a Novel NRG1 Fusion with Targeted Therapeutic Implications in Locally Advanced Pediatric Cholangiocarcinoma: A Case Report
12. Abstract 3552: YAP-TEAD2 binding mediates therapy resistance in RAS-driven neuroblastoma
13. Abstract 911: Butyrophilin 3A2 expression plays a critical role in phosphoantigen-mediated γδ T cell cytotoxicity of neuroblastoma cells
14. Abstract 4093: Dual targeted CAR immunotherapy for neuroblastoma using γδ T cells
15. Abstract 3545: The Yes-associated protein (YAP) regulates GD2 immunotherapy response in high-risk neuroblastoma
16. Supplementary Materials and Methods from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
17. Data from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
18. Supplementary Data from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
19. Figure S5, Figure S6 from YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma
20. Figure S4 from YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma
21. Figure S1, Figure S2, Figure S3 from YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma
22. Table S3, Table S4 from YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma
23. Data from Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma
24. Supplementary Figure 1 from Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma
25. Supplementary Table 2 from Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma
26. Supplementary Table 1 from Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma
27. Supplementary Figure 2 from Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma
28. Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma
29. Children's Oncology Group's 2023 blueprint for research: Neuroblastoma.
30. Concurrent myeloid sarcoma, atypical teratoid/rhabdoid tumor, and hypereosinophilia in an infant with a germline SMARCB1 mutation
31. A 3D Bioprinted in vitro Model of Neuroblastoma Recapitulates Dynamic Tumor‐Endothelial Cell Interactions Contributing to Solid Tumor Aggressive Behavior (Adv. Sci. 23/2022)
32. Phase I study of 131I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.
33. Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.
34. Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials
35. Targeting TRIP13 in Wilms Tumor with Nuclear Export Inhibitors
36. Identification and Targeting of Protein Tyrosine Kinase 7 (PTK7) as an Immunotherapy Candidate for Neuroblastoma Cellular Therapy
37. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium
38. A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment
39. Abstract 1547: Defining the optimal source of allogeneic γ δ T cells for novel cellular therapy approaches in neuroblastoma
40. High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
41. High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
42. Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance
43. Contributors
44. Renal Neoplasms
45. YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma
46. The first report of pediatric patients with solid tumors treated with venetoclax.
47. Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.
48. A phase I study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
49. Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.
50. Multidisciplinary Care of Adult Wilms’ Tumor During Pregnancy: A Case Report and Review of the Literature
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.